UNSPSC 51201818: Roquinimex

This classification denotes an immunostimulant and angiogenesis activator inhibitor with the molecular formula C18H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 372T2944C0, chemically known as 1,2-dihydro-4-hydroxy-n,1-dimethyl-2-oxo-3-quinolinecarboxanilide but generally known as roquinimex, which bears US NIH Compound Identifier 55197. European Medicines Agency schedules Roquinimex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10384MIG.

UNSPSC 51201818 Roquinimex is a Commodity code covering pharmaceutical products, specifically the antimalarial drug roquinimex that state and local health departments procure for disease prevention and treatment programs. The code appears in state procurement activity as part of broader vaccine and pharmaceutical sourcing, though recent posted opportunities under this specific code are sparse.

The Mississippi State Department of Health posted a sole source procurement notice on July 13, 2026 for Yellow Fever Vaccine from Sanofi Pasteur, Inc., with objections due August 3, 2026. This notice does not represent a competitive solicitation but rather a proposed sole source designation; the department must substantiate that no alternative vendors can supply the vaccine, and any entity objecting to sole source classification may submit written notice with supporting documentation demonstrating alternative supply. The notice did not specify quantity, contract term, estimated value, or pricing. Beyond this Mississippi health department notice, the source shows no other recent state or local contract opportunities tagged to this code.